QUININE COMPOUNDS, METHOD FOR THEIR PRODUCTION AND THEIR MEDICAL APPLICATION Russian patent published in 2018 - IPC C07D453/02 A61K31/49 A61P1/00 A61P11/00 A61P13/00 

FIELD: pharmacology.

SUBSTANCE: invention relates to a compound of formula I

or a pharmaceutically acceptable salt or optical isomer thereof, wherein, in formula I, n is selected from 1 to 7, R₁ means C₃-C₇ hydrocarbyl, which may be unsubstituted or optionally substituted by halogen, alkoxy, alkoxycarbonyl, heterocyclyl or aryl; R₂ is aryl or heteroaryl containing one or more heteroatoms selected from N, O or S which may be unsubstituted or optionally substituted by one or more substituents of halogen, phenyl, -OR₆, -SR₆, -NR₆R₇, -NHCOR₆, -CONR₆R₇, -CN, -NO₂, -COOR₆, -CF₃ or linear or branched C₁-C₄ hydrocarbyl, R₆ and R₇ can denote a hydrogen atom or linear or branched C₁-C₄ hydrocarbyl; R₃ is hydroxyl, halogen, alkoxy or acyloxy. Alkoxy or acyloxy may be unsubstituted or optionally substituted by halogen, hydroxyl, alkoxy, hydrocarbyl, alkoxyhydrocarbyl, heterocyclyl or aryl; R₄ and R₅ may or may not be present, and, independently, can mean, without limitation, a substituent such as halogen, hydroxyl, alkoxy, hydrocarbyl, alkoxyhydrocarbyl, heterocyclyl or aryl when these radicals are present. Y is linear or branched C₁-C₇ alkyl or - (CH₂-O-CH₂)_m-, which may be optionally substituted by halogen, hydroxyl, alkoxy, alkoxyalkyl, unsaturated hydrocarbyl, cyclic hydrocarbyl or heterocyclyl. M is 1-3; X^- means an acid residue or hydroxyl, the said compounds having a selective antagonistic effect on the M₁ and M₃ receptors subtypes, but insignificantly affect the M₂ receptor subtype.

EFFECT: compound application efficiency increase.

24 cl, 5 tbl, 33 ex